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ABSTRACT
Introduction: Psoriasis is a common, long-term
skin condition associated with high levels of
psychological distress and considerable life
impact. The impact of psoriasis, beyond the
skin, is often not recognised and under-treated.
Methods: This paper explores the relationship
between psychological distress and psoriasis
including reference to the ‘brain–skin access’.
The life impact of psoriasis is discussed and
pharmacological interventions which affect
distress associated with psoriasis and
psychological interventions are reviewed.
Evidence from peer-reviewed journals and
controlled trials inform the text.
Results: Psoriasis has a profound impact on
mental health and well-being which is under-
recognised by clinicians. The sympathetic
adrenal medullary axis and hypothalamic
pituitary adrenal axis are likely to be involved
in the onset of psoriasis and there may also be
an effect from inflammation in the skin on the
central release of corticotrophin-releasing
hormone. Psoriasis can be stigmatising and
may affect all aspects of life including
relationships, employment, social life and
leisure activities. There is some evidence for
psychological interventions being effective in
the management of distress associated with
psoriasis and psoriasis itself. Studies, however,
have used disparate outcomes and methods and
largely involve low numbers of patients. There
is very limited access to psychological support
for the patients with psoriasis despite evidence
of high levels of psychological distress and
considerable life impact.
Conclusions: Psoriasis is a long-term skin
condition associated with high levels of
distress and considerable life impact, both of
which are under-recognised. Routine screening
for distress with access to effective treatment is
required. There is a need for high-quality
studies to assess the effect of psychological
intervention in patients with psoriasis both to
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inform guidance and facilitate the provision of
effective psychological support services.





Psoriasis affects approximately 1.2 million
people in the UK [1]. The profound impact of
psoriasis on mental health, well-being and
quality of life is increasingly recognised [2–4].
The burden of living with psoriasis is equivalent
or greater than that of other long-term
conditions such as congestive cardiac failure
and chronic lung disease [5], but tends to be
under-recognised [6]. There is limited evidence
regarding the management of stress and distress
associated with psoriasis [7] and even less scope
within our present health system for
psychological intervention [8].
This article reviews the relationship between
distress and psoriasis, exploring the life impact of
psoriasis and the current evidence for pharma-
cological and psychological interventions in this
population. Papers from peer-reviewed journals
have been used to inform the text and all





Distress, in the form of excessive worrying,
impairs clearance of psoriasis during
phototherapy [9]. Retrospective studies have
demonstrated that 37–88% of patients believe
that their psoriasis is caused or exacerbated by
stress [10–12]. In prospective studies, Verhoeven
et al. [13] confirmed that daily stressors trigger
increased itch and psoriasis severity, and that
patients with high levels of worrying are most
vulnerable to the impact of stressors [14].
Psychoneuroimmunology: The Brain–Skin
Axis (Fig. 1)
The stress response is an evolutionary
mechanism enabling both a rapid (fight or
flight) response to an acute stressor (e.g.
avoiding a predator) and a response to chronic
stress by saving energy [15]. Modern day
stressors trigger established pathophysiological
pathways, which can act as exacerbating or
causative factors in inflammatory disease [16].
Hypothalamic–Pituitary–Adrenal Axis
Activation of neuro-hormones by stress is
predominantly via the hypothalamic–
pituitary–adrenal (HPA) axis with up-
regulation of corticotrophin-releasing
hormone (CRH), adrenocorticotrophic
hormone and glucocorticoids [17], alongside
neuropeptide stress response mediators [18].
The immune system is profoundly altered:
glucocorticoids inhibit interleukin (IL)-12,
interferon-gamma and tumour necrosis factor
(TNF) via antigen-presenting cells and T-helper
(Th)1 cells. IL-4, IL-10 and IL-13 are up-
regulated via Th2 cells. Cortisol exerts an
immunosuppressive effect shifting Th1 to Th2-
mediated immunity [19]. CRH also directly
affects localised inflammatory responses [20].
Skin has a fully functional peripheral HPA axis
that translates and co-ordinates the peripheral
stress response from the central HPA axis,
creating its own cutaneous homeostasis [21].
Neuropeptides, substance P and nerve growth
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factor facilitate communication between
neuronal and immune cells, and promote
migration of macrophages and monocytes
through vascular endothelium. [22].
Very interestingly, the cutaneous immune
system may also regulate the central nervous
system. Mast-cell histamine increases the
expression of CRH messenger RNA in the
hypothalamus of dogs [23], and IL-1 and IL-6
(elevated in psoriasis) trigger CRH release [24].
Furthermore, pro-inflammatory cytokines can























Fig. 1 The brain–skin axis. ACTH adrenocorticotropic hormone, NGP nerve growth factor, SP substance P, Th 0-2
Thelper 0-2 cells, ? up-regulation of CRH by the cutaneous inﬂammatory response
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symptoms [25]. This raises the question of
whether psoriasis triggers stress or stress
triggers psoriasis, or both.
Low cortisol levels in people with psoriasis
who describe themselves as stress responders
and who have a blunted HPA axis response to
acute social stress in psoriasis [26] may result in
hypocortisolism and partly explains the
immune overactivity involved in psoriatic flares.
Sympathetic–Adrenal–Medullary Axis
While the HPA axis tends to be involved in slow
and sustained responses to stressors [27], the
sympathetic–adrenal–medullary axis is
activated within seconds of a stressful stimulus.
Catecholamines are released, activating CD4?
lymphocytes and trafficking of lymphocytes
into the skin; an event that precedes the
development of psoriatic plaques [28].
Psychiatric Co-Morbidity
The prevalence of depression in psoriasis is
estimated to be up to 30% [29]. Fortune et al.
[30] identified 38% of 140 patients with
psoriasis as pathological worriers, while Gupta
and Gupta [31] found that 5.5% of patients with
psoriasis had active suicidal ideation and that
9.5% expressed a death wish.
A UK population-based cohort study of
146,042 patients [4] demonstrated an
increased incidence of diagnoses of depression,
anxiety and suicidality in psoriasis; the authors
estimated that over 10,400 diagnoses of
depression, 7,100 diagnoses of anxiety, and
350 diagnoses of suicidality were attributable
to psoriasis each year.
Accurate epidemiology of psychiatric co-
morbidity is limited by disparities in
methodologies, with some studies using
symptom questionnaires to diagnose
depression and others employing clinical
diagnosis alone. Most studies lack a control
group and are cross-sectional in nature,
preventing determination of causal
relationships.
A recent study suggests that maladaptive
schema-level cognitions may underlie the
psychological distress experienced by people
with psoriasis [32]. Mizara et al. [32]
investigated the relationship between
maladaptive schemas and psychological distress
in patients with psoriasis. Three schemas—
vulnerability to harm, defectiveness and social
isolation—predicted anxiety and depression.
Despite evidence for psychiatric morbidity,
most guidelines regarding psoriasis do not
include screening for anxiety and depression;
hence patients may not receive appropriate
intervention.
Disease Severity and Psychological Impact
Psychological and psychiatric symptoms are
generally in keeping with disease severity [33,
34], but not universally [33, 35]. In a
prospective study of 72 patients undergoing
phototherapy, Fortune et al. [36] demonstrated
significant improvement in psoriasis, without
change in anxiety, depression or worrying. In
another prospective study, Gupta et al. [35]
found that 16 of 98 patients receiving
phototherapy had persistent or worsening
psoriasis disability index scores despite an
improvement in psoriasis. Sampogna et al. [33]
reported persistent psychiatric disorder with
clearance of psoriasis in one-third of subjects.
The lack of correlation between
psychological impact and physical severity in
some patients may be due to the cumulative
impact of living with psoriasis [2], maintenance
of distress by established maladaptive schemas
and coping responses [32], or by psoriasis
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affecting ‘high impact’ sites [37]. Lower levels of
distress have been reported with longer disease
duration [38, 39], which may indicate
psychological acceptance, or reflect long-term
adaptation [40] and avoidance of activities that
trigger distress. The latter hypothesis is
supported by Kleyn et al. [41] in a study using
functional magnetic resonance imaging, which
demonstrated reduced signal responses to
disgusted faces in patients with psoriasis
compared with controls, suggesting coping
mechanisms among those with psoriasis to
prevent distress when seeing disgusted facial
expressions.
Recognition of Distress by Clinicians
Clinicians and patients may differ in their
assessment of disease severity and health-
related quality of life (HRQoL). In a study
comparing a checklist completed by both
dermatologists and patients [42], patients
ranked ‘‘embarrassment over one’s appearance’’
as the most severe feature of psoriasis, whereas
dermatologists ranked it the lowest feature.
Patient-, rather than clinician-rated severity is
the strongest predictor of HRQoL impairment
[2, 33, 43]. Richards et al. [44] assessed 43
outpatient consultations where self-report
questionnaires indicated that 37% and 12% of
patients had clinical anxiety and depression,
respectively. The dermatologist discussed
psychological difficulties in only 39% of
consultations with significantly distressed
patients. There was poor correlation between
the patient and clinician regarding the presence
of anxiety and depression.
The discrepancy between patients and
clinicians is probably multi-factorial. Patients’
own underlying perceptions of illness, coping
strategies [43–46], personality traits [32], and
body shame contribute to distress and are
factors often unexplored by clinicians.
Richards et al. [47] found that 33% of 300
patients with psoriasis had alexithymia
(impaired ability to build mental
representations of emotions and express
emotions). This may limit a patient’s ability
to communicate emotions effectively and lead
to the misinterpretation of emotional arousal
as physical illness. People with psoriasis may be
reluctant to disclose personal information
through fear of rejection and previous
experience of clinicians’ lack of empathy
[3, 45].
SOCIAL IMPACT OF PSORIASIS
Stigmatisation
Psoriasis may attract attention, and cause
avoidance, public rejection and reactions of
disgust. Ginsburg and Link [48] identified six
main areas associated with stigma: anticipation
of rejection; feelings of being flawed; sensitivity
to others’ attitudes; guilt and shame;
secretiveness; and positive attitudes. The main
predictors of stigma were: younger age at onset;
extent of bleeding; employment status;
duration of disease; and rejection experience.
Hrehoro´w et al. [49] repeated the study in 2012
and found that over 78% of patients had high
levels of stigmatisation. Stigmatising
experiences appear to be very common.
Ginsburg et al. [50] found that 99 of 100
patients described experiencing stigmatising
events and Gupta et al. [51] reported that 26%
of patients had experienced public rejection.
Recently, Sampogna et al. [3] found that 37% of
patients experienced humiliation often or all
the time, and that shame was one of the most
frequently reported emotions.
Feelings of shame and stigmatisation can
lead to avoidance of sporting activity, social
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opportunities, intimacy and public places. It
may also affect access to health care, with
patients reluctant to expose their skin even to
a doctor.
Relationships
Eghlileb et al. [52] interviewed family members
of patients with psoriasis; 57% described
psychological distress, 55% social disruption,
44% limitations to leisure activities and 37%
deterioration of close relationships. The
patient’s level of distress was more closely
related to the family members’ level of distress
and social disruption than the severity of
psoriasis. In a multicentre, case-controlled
study, Poot et al. [53] found severe family
dysfunction to be 16-fold more likely in
patients with psoriasis than in families
without a skin condition.
Psoriasis also affects sexual functioning. In
Gupta and Gupta’s cross-sectional survey of 120
inpatients, 40% reported a decline in sexual
activity since the onset of psoriasis. This decline
was associated with joint pains, but not psoriasis
severity [54]. Sampogna et al. [55] confirmed the
impaired sexual life of 936 inpatients with
psoriasis. Using individual questions relating to
sexual functioning from dermatology- and
psoriasis-specific questionnaires, they found
that 35.571.3% of patients reported sexual
problems. In contrast to the Gupta and Gupta
findings, psoriasis severity and psychological
problems were associated with sexual
functioning. In neither study was the presence
of genital lesions determined.
In a cross-sectional study of 92 male patients
with psoriasis, Goulding et al. [56] found an
increased prevalence of erectile dysfunction (ED)
(58%) compared with controls with other skin
conditions (49%). Psoriasis was not an
independent risk factor for ED. The link between
psoriasis, ED and atherosclerosis was suggested as
a mechanism for sexual dysfunction.
Difficulties in relationships are unsurprising
in a condition with high levels of distress and
stigma. Despite this, the quality of relationships
and sexual functioning are not routinely
included in consultations or as outcomes of
studies.
Employment and Financial Burden
The choice of employment or career, and
therefore income, is affected by psoriasis [57–
59]. In one study, 40% of patients reported
experiencing major difficulties at work [52] and
in another, 2% stopped work due to psoriasis [57].
There is an inverse relationship between psoriasis
severity, employment and income [59–62]. In a
study of 601 patients by Horn et al., 31.2% of
patients with severe psoriasis had a low income
(less than US$30,000) compared with 18.1% of
patients with mild psoriasis [59]. Approximately
20% were unemployed. Significantly more
patients with severe psoriasis (17%) reported
their psoriasis as the reason for unemployment
compared with patients with mild psoriasis (6%).
Though the results were consistent with other
studies [60–62], its cross-sectional design prevents
determination of causal relationships.
Recently, biological intervention studies
have incorporated broader ‘life impairment’
outcomes into their study designs. Psoriasis-
related work productivity and activity
impairment (WPAI) are significantly improved
by treatment with adalimumab [61]. Treatment
with ustekinumab is linked with an
improvement in productivity and reduced
absenteeism [60]. Both studies show strong
correlations between disease severity and work
disability. Kimball et al. [61] reported that a
reduction in Dermatology Life Quality Index
(DLQI) was more highly correlated with WPAI
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outcomes than an improvement in Psoriasis
Area Severity Index (PASI) score, and Reich et al.
[60] reported a greater improvement in WPAI
outcomes in patients with higher DLQI scores
and Hospital Anxiety and Depression Score at
baseline, suggesting that a reduction in work
disability may only be partially attributable to
an improvement in disease severity.
Alcohol and Smoking Misuse
Alcohol and cigarette misuse are common
among patients with psoriasis [63, 64]. Kirby
et al. [65] reported excess alcohol consumption
to be up to 50%. Mills et al. [66] found that
twice as many patients with psoriasis smoked
compared with controls. Alcohol exacerbates
psoriasis severity and pruritus, and impairs
treatment response [67]. Poikolainen et al. [68]
demonstrated an increased standardised
mortality ratio in all parameters of alcohol-
and smoking-related causes in people with
psoriasis. Naldi et al. [69] found that the risk
of psoriasis was higher (but not significantly) for
current smokers and drinkers, and a trend for
increased risk of psoriasis with increased usage





TNF-a antagonists are safe and effective in
improving both the physical severity of
psoriasis and HRQoL [71–73]. Patients with
depression also have increased levels of TNF-a
[74]. It is speculated that TNF is related to
fatigue and sleepiness, and may account for the
coexistence of depression with fatigue [75, 76].
TNF-a antagonists may reverse depressive
symptoms and fatigue in patients with
psoriasis [61, 74, 77]. Reductions in anxiety
and depression scores have also been
demonstrated with ustekinumab (an anti-IL-
12/23 agent used to treat psoriasis) [78].
Psychotropic Medications
Few studies have investigated the role of
psychotropic medications in psoriasis. A double-
blind, placebo-controlled study by Alpsoy et al.
[79] compared treatment with moclobemide (a
monoamine oxidase inhibitor antidepressant)
plus topical corticosteroid to treatment with
topical corticosteroid alone in 60 patients.
Improvements in PASI, depression and anxiety
scores were significantly greater in the
moclobemide group at 6 weeks compared with
topical corticosteroid alone. Baseline PASI scores,
however, were low (\5) in both groups, making it
difficult to evaluate changes in scores. A recent
retrospective open study of 38 patients with
moderate/severe psoriasis and depressive and/or
anxiety disorders who recently started anti-TNFa
therapy compared treatment with escitalopram (a
serotonin selective reuptake inhibitor) plus
psychotherapeutic support with
psychotherapeutic support alone [80]. Reduced
depression and anxiety scores, and pruritus and
PASI scores were seen in the escitalopram plus
psychotherapeutic support group compared with
psychotherapeutic support only. No details of the
‘psychotherapeutic support’ were given and
randomisation was by patient preference.
The evidence for psychotropic medications
and psoriasis is conflicting, with several case-
reports of fluoxetine-induced or -exacerbated
psoriasis [81–83], while the atypical
antidepressant, bupropion, has been linked to
exacerbations of psoriasis [84]. In addition, the
mood stabiliser, lithium, commonly
precipitates or aggravates psoriasis [85].
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Psychological Interventions
Despite the association of distress with psoriasis,
evidence for a ‘brain–skin axis’ and the effect of
stress on immune functioning and disease
severity, there have been few high-quality
studies investigating the effectiveness of
psychological interventions. A recent meta-
analysis of psychological interventions
designed to improve skin condition outcomes
identified only eight studies involving psoriasis
that fulfilled the criteria of having a control
group, being published in a peer-reviewed
journal and written in English [7]. The
majority of these studies had small sample
sizes and non-randomised study designs. A
diverse range of psychological interventions
with differing outcomes were included,
making comparisons impossible.
Psychological interventions can be divided
into those addressing cognitive and behavioural
processes—cognitive behaviour therapy
(CBT)—and those targeting a reduction in
stress (arousal reduction).
Arousal Reduction
A prospective, randomised, single-blinded study
by Kabat-Zinn et al. [86] introduced a
mindfulness meditation-based stress reduction
audio-tape intervention as an adjunct to
phototherapy and compared it to phototherapy
alone. A significant improvement in the rate of
psoriasis clearance and a non-significant
reduction in stress levels were found. The
duration of remission was not assessed.
Gaston et al. [87] performed a single-blinded,
randomised, controlled trial comparing
20 weeks of meditation or meditation plus
imagery with a waiting list control group or
treatment-free group. A significant
improvement in psoriasis severity (P B 0.01)
was seen in the meditation intervention
groups, with no additional benefit of imagery.
Psychological outcomes were not evaluated and
patient numbers were small.
Vedhara et al. [88] evaluated the effects of an
emotional disclosure programme. Patients with
psoriasis were asked to spend 20 min writing or
talking about their thoughts or the most
upsetting times of their lives on four
consecutive days. A control group wrote a
factual (non-emotional) account of the
previous day. They found no difference in
psoriasis severity between the two groups;
however, changes in mood predicted psoriasis
severity in the intervention group only.
Assessments were at 12 weeks after the
intervention. Paradisi et al. [89] compared the
efficacy of two different written emotional
disclosure techniques performed on three
consecutive days with a control group in
patients undergoing phototherapy. The results
were difficult to interpret, but appeared to
demonstrate a slightly longer duration of
remission in one of the emotional disclosure
groups. Both of these studies had a very short
duration of intervention. The inclusion of
emotional disclosure techniques on a more
regular basis may warrant further investigation.
Hypnosis
A potential role for hypnosis has been
demonstrated in two studies [90–92]. Tausk and
Whitmore [91] randomised highly or moderately
hypnotisable patients with psoriasis to either
hypnosis with active suggestions of
improvement or neutral hypnosis. No
difference in PASI scores was found between the
two groups, although there was a suggestion that
highly hypnotisable patients in both groups
demonstrated a greater percentage reduction in
PASI score than moderately hypnotisable
patients (P = 0.01). Patient numbers, however,
were very low and there was no non-intervention
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control group. Price et al. [92] employed self-
hypnosis, together with relaxation and support
group discussions over eight weekly sessions in a
matched-controlled trial. A significant reduction
in anxiety and neuroticism, and an increase in
self-esteem, maintained at 6 months, were
demonstrated. No significant improvement in
psoriasis severity was found. Both studies are
limited by small group size and the improvement
seen in the study by Price et al. cannot be
concluded as the sole benefit of self-hypnosis
training. Hypnosis may, however, be a
therapeutic modality that warrants further
testing.
Cognitive Behaviour Therapy
Individual coping strategies, illness perceptions,
beliefs about control and curability of illness, and
individual personality traits are closely linked
with health outcomes and psychological distress
in psoriasis [46, 93–95]. Only two studies,
however, have investigated CBT as an adjunctive
treatment for psoriasis. A high-quality, case-
controlled study by Fortune et al. [96] involving
40 patients with psoriasis receiving adjunctive
group CBT demonstrated a significant reduction
in PASI scores at 6 weeks and 6 months follow-up,
with 64% of patients achieving [75% psoriasis
clearance at 6-month follow-up compared with
23% of the control group. The CBT group also
showed reductions in anxiety and depression
scores, and almost double the reduction in self-
reported disability and life stress scores at 6-week
and 6-month follow-ups.
In a randomised, controlled trial, Zacharie
et al. [97] compared the effect of seven individual
psychotherapy sessions—which included
imagery, stress management and relaxation
training over a 12-week period—with a control
therapy in 51 patients with psoriasis. Slight, but
significant, reductions in reference lesion
severity and a non-significant trend for overall
reduction in psoriasis severity were observed in
the psychotherapy test group. Perceived stress
remained unchanged. This study, however,
combined arousal reduction with a cognitive
intervention. Further studies investigating the
effectiveness of CBT, including work- and
relationship-related outcomes, are warranted.
DISCUSSION
Psoriasis is a common, visible, long-term
condition with a considerable psychological
and life impact, potentially affecting every
aspect of an individual’s existence including
work, recreation, relationships, sexual
functioning, family and social life.
Increasing awareness of the life impact of
psoriasis has led to clinical guidelines that
include the evaluation of patients’ HRQoL in
addition to physical severity [98–100]. European
evidence-based (S3) clinical guidelines propose
a DLQI of 0 or 1 as a treatment goal [99], and
Scottish Intercollegiate Guidelines Network
guidance states that the ‘‘assessment of
patients with psoriasis or psoriatic arthritis
should include psychosocial measures, with
referral to mental health services as
appropriate’’, and recommends at least annual
screening for depressive symptoms [100].
Despite high levels of psychological distress,
the provision of psychology services in the UK
for patients with skin disease is, at best, limited.
In spite of clear demand, only 4% of
dermatology units in the UK provide a
dedicated counselling service [101]. Despite
attempts to increase awareness and the
provision of resources by groups such as the
British Association of Dermatologists and
Psoriasis Association, psychology services
provision has, in fact, deteriorated since
2004 [101].
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Good-quality evidence to support the
instigation of dedicated psychology services for
patients with psoriasis and other skin conditions
is presently limited. Existing data for
psychological interventions mainly come from
studies that lack consistency in design and
outcome measurements. The effect of
psychological intervention on work,
relationships and the need for systemic
therapies, which would make these services
cost-effective, has not been investigated
adequately. The degree of heterogeneity in the
studies prevents further extrapolation of results.
There is a need for well-designed, adequately
powered and well-controlled interventional
studies to investigate the optimal psychological
interventions for people with psoriasis. These
data are required not only to inform future
provision of psychological services for this
population of patients who are presently under-
supported, but also to provide hard evidence for
the efficacy of such interventions as part of the
successful management of psoriasis.
However, there is cause for optimism.
Routinely measuring PASI and DLQI and
asking about the life impact of psoriasis in
clinics is a manageable start, even without
dedicated psychology resources. Screening for
psychological distress would detect un-
diagnosed cases of anxiety and depression,
enabling patients to be directed towards
services that may offer treatment. Increased
recognition of the psychological and life impact
of psoriasis among clinicians is the first step
towards improving care.
An understanding of the links between
physical and psychological health is increasing.
Government initiatives, such as ‘No Health
Without Mental Health’ may help transform
understanding into service improvement [102].
The future management of psoriasis may
routinely involve multi-disciplinary teams to
manage physical, psychological and social
aspects of the condition in line with other
systemic long-term conditions.
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